GB0010068D0 - Vaccine composition - Google Patents

Vaccine composition

Info

Publication number
GB0010068D0
GB0010068D0 GBGB0010068.5A GB0010068A GB0010068D0 GB 0010068 D0 GB0010068 D0 GB 0010068D0 GB 0010068 A GB0010068 A GB 0010068A GB 0010068 D0 GB0010068 D0 GB 0010068D0
Authority
GB
United Kingdom
Prior art keywords
vaccine composition
ectoparasites
cement proteins
tick cement
ectoparasite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0010068.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evolutec Ltd
Original Assignee
Evolutec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evolutec Ltd filed Critical Evolutec Ltd
Priority to GBGB0010068.5A priority Critical patent/GB0010068D0/en
Publication of GB0010068D0 publication Critical patent/GB0010068D0/en
Priority to GBGB0028606.2A priority patent/GB0028606D0/en
Priority to AU50512/01A priority patent/AU781622B2/en
Priority to PCT/GB2001/001834 priority patent/WO2001080881A1/en
Priority to BR0110278-8A priority patent/BR0110278A/en
Priority to MXPA02010417A priority patent/MXPA02010417A/en
Priority to EP01923827A priority patent/EP1283716B1/en
Priority to CNA2008102142020A priority patent/CN101406696A/en
Priority to CA2405537A priority patent/CA2405537C/en
Priority to JP2001577978A priority patent/JP4925236B2/en
Priority to AT01923827T priority patent/ATE551068T1/en
Priority to CNB018117589A priority patent/CN100558399C/en
Priority to NZ522301A priority patent/NZ522301A/en
Priority to CU20020238A priority patent/CU23358B7/en
Priority to US10/280,114 priority patent/US20030170257A1/en
Priority to US11/288,668 priority patent/US20070031411A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0003Invertebrate antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Insects & Arthropods (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to the use of tick cement proteins in the production of vaccines for protecting animals against the bite of blood-sucking ectoparasites and against the transmission of viruses, bacteria and other pathogens by such ectoparasites. When used as vaccine components, the tick cement proteins of the invention confer broad cross-reactivity against a variety of species of ectoparasite.
GBGB0010068.5A 2000-04-25 2000-04-25 Vaccine composition Ceased GB0010068D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0010068.5A GB0010068D0 (en) 2000-04-25 2000-04-25 Vaccine composition
GBGB0028606.2A GB0028606D0 (en) 2000-04-25 2000-11-23 Vaccine composition
NZ522301A NZ522301A (en) 2000-04-25 2001-04-25 Vaccine comprising a tick cement protein
EP01923827A EP1283716B1 (en) 2000-04-25 2001-04-25 Vaccine comprising a tick cement protein
JP2001577978A JP4925236B2 (en) 2000-04-25 2001-04-25 Vaccine containing tick cement protein
BR0110278-8A BR0110278A (en) 2000-04-25 2001-04-25 A vaccine, antibody or antiserum composition, methods of producing an antibody or antiserum and immunizing an animal against a blood-eating ectoparasite, tick cement protein, and use of a protein tick cement
MXPA02010417A MXPA02010417A (en) 2000-04-25 2001-04-25 Vaccine comprising a tick cement protein.
AU50512/01A AU781622B2 (en) 2000-04-25 2001-04-25 Vaccine comprising a tick cement protein
CNA2008102142020A CN101406696A (en) 2000-04-25 2001-04-25 Vaccine comprising a tick cement protein
CA2405537A CA2405537C (en) 2000-04-25 2001-04-25 Vaccine comprising a tick cement protein
PCT/GB2001/001834 WO2001080881A1 (en) 2000-04-25 2001-04-25 Vaccine comprising a tick cement protein
AT01923827T ATE551068T1 (en) 2000-04-25 2001-04-25 TICK CEMENT PROTEIN CONTAINING VACCINE
CNB018117589A CN100558399C (en) 2000-04-25 2001-04-25 The vaccine that contains a kind of tick cement protein
CU20020238A CU23358B7 (en) 2000-04-25 2002-04-25 VACCINE THAT INCLUDES A GARRAPATA CEMENT PROTEIN
US10/280,114 US20030170257A1 (en) 2000-04-25 2002-10-24 Vaccine comprising a tick cement protein
US11/288,668 US20070031411A1 (en) 2000-04-25 2005-11-29 Vaccine comprising a tick cement protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0010068.5A GB0010068D0 (en) 2000-04-25 2000-04-25 Vaccine composition

Publications (1)

Publication Number Publication Date
GB0010068D0 true GB0010068D0 (en) 2000-06-14

Family

ID=9890483

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0010068.5A Ceased GB0010068D0 (en) 2000-04-25 2000-04-25 Vaccine composition
GBGB0028606.2A Ceased GB0028606D0 (en) 2000-04-25 2000-11-23 Vaccine composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
GBGB0028606.2A Ceased GB0028606D0 (en) 2000-04-25 2000-11-23 Vaccine composition

Country Status (5)

Country Link
JP (1) JP4925236B2 (en)
CN (1) CN101406696A (en)
AT (1) ATE551068T1 (en)
CU (1) CU23358B7 (en)
GB (2) GB0010068D0 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110540583B (en) * 2018-05-29 2022-07-15 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) Sickle rhipicephalus vacuole sortilin molecule and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723945D0 (en) * 1997-11-12 1998-01-07 Nat Environmental Research Cou Tissue cement

Also Published As

Publication number Publication date
CU23358B7 (en) 2009-03-16
CN101406696A (en) 2009-04-15
JP4925236B2 (en) 2012-04-25
ATE551068T1 (en) 2012-04-15
JP2003531177A (en) 2003-10-21
GB0028606D0 (en) 2001-01-10

Similar Documents

Publication Publication Date Title
WO2004030608A3 (en) Nanoemulsion vaccines
DE602004024542D1 (en) SUB-VACCINE AGAINST THE RESPIRATORY SYNZYTIALVIRUS
DE60039198D1 (en) Adjuvant compositions for increasing the immune response to polynucleotide-based vaccines
GB0103169D0 (en) Vaccine composition
WO2008048289A3 (en) Salmonella based oral vaccines for anthrax
DE602004028029D1 (en) Rwendung
WO2009077577A3 (en) Vaccine antigens from piscirickettsia salmonis
DE60136563D1 (en) SALMONELLA VACCINE
BR0110278A (en) A vaccine, antibody or antiserum composition, methods of producing an antibody or antiserum and immunizing an animal against a blood-eating ectoparasite, tick cement protein, and use of a protein tick cement
EP1471936A4 (en) Hiv vaccine and method of use
NO20062469L (en) Streptococcus phocae vaccine
WO2003023041A3 (en) Infectious and attenuated bovine viral diarrhea virus clone; methods for their production and use
DK1395283T3 (en) Heterologous protection induced by immunization with Invaplex vaccine
GB0010068D0 (en) Vaccine composition
GB9723945D0 (en) Tissue cement
AP2049A (en) Medicament containing activated antithrombin III
NO20010140L (en) Chemotaxin-inhibiting protein of Staphylococcus (CHIPS) and its use
EP1556081A4 (en) Recombinant intracellular pathogen immunogenic compositions and methods for use
EP1303300A4 (en) Compositions and methods for treatment of candidiasis
WO2003049670A3 (en) Adjuvant formulations for bacterial and virus vaccines and method of making same
DE60238554D1 (en) Vaccine against Infectious Diseases
WO2004082596A3 (en) Yersinia species compositions
HU0002228D0 (en) Line attenuated bacteria for use in a vaccine
HUP9700975A2 (en) Live attenuated rtx-producing bacteria of the family pasteurellaceae
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)